Catheter Precision Announces Successful LockeT Launch in South Africa
Catheter Precision (NYSE:VTAK) announced rapid commercial uptake of its LockeT closure device in South Africa on Nov 20, 2025. With distributor HLC Medical and Dr. Heather Henry-Lines, LockeT was implemented in five hospitals within two months; three hospitals use LockeT daily and two use it routinely. Two additional hospitals are awaiting internal approvals. All five hospitals have placed reorders through the distributor. Management highlighted LockeT as cost effective, workflow-improving, and supportive of rapid hemostasis enabling same-day discharge.
Catheter Precision (NYSE:VTAK) ha annunciato una rapida diffusione commerciale del dispositivo di chiusura LockeT in Sud Africa il 20 novembre 2025. Con il distributore HLC Medical e la dottoressa Heather Henry-Lines, LockeT è stato implementato in cinque ospedali in due mesi; tre ospedali usano LockeT quotidianamente e due in modo routinario. Altri due ospedali hanno in attesa di approvazioni interne. Tutti e cinque gli ospedali hanno effettuato nuovi ordini tramite il distributore. La direzione ha evidenziato che LockeT è conveniente, migliora il flusso di lavoro e supporta l'emostasi rapida che permette la dimissione nello stesso giorno.
Catheter Precision (NYSE:VTAK) anunció una rápida adopción comercial de su dispositivo de cierre LockeT en Sudáfrica el 20 de noviembre de 2025. Con el distribuidor HLC Medical y la Dra. Heather Henry-Lines, LockeT se implementó en cinco hospitales en dos meses; tres hospitales usan LockeT a diario y dos de forma rutinaria. Dos hospitales adicionales están a la espera de aprobaciones internas. Los cinco hospitales han realizado nuevos pedidos a través del distribuidor. La dirección destacó que LockeT es rentable, mejora el flujo de trabajo y facilita una hemostasia rápida que permite el alta el mismo día.
Catheter Precision (NYSE:VTAK)가 남아프리카에서 LockeT 폐쇄 기기의 상업적 조기 채택을 2025년 11월 20일에 발표했습니다. 유통사 HLC Medical와 Dr. Heather Henry-Lines와 함께 LockeT는 두 달 만에 다섯 개 병원에 도입되었고; 세 병원은 매일 LockeT를 사용하고 두 병원은 정기적으로 사용합니다. 내부 승인을 기다리는 추가로 두 병원이 있습니다. 다섯 병원 모두 유통사를 통해 재주문을 했습니다. 경영진은 LockeT가 비용 효율적이고 작업 흐름을 개선하며 신속한 지혈을 지원해 같은 날 퇴원이 가능하다고 강조했습니다.
Catheter Precision (NYSE:VTAK) a annoncé une adoption commerciale rapide de son dispositif de fermeture LockeT en Afrique du Sud le 20 novembre 2025. Avec le distributeur HLC Medical et le docteur Heather Henry-Lines, LockeT a été mis en œuvre dans cinq hôpitaux en deux mois ; trois hôpitaux utilisent LockeT quotidiennement et deux de manière routinière. Deux hôpitaux supplémentaires attendent des approbations internes. Tous les cinq hôpitaux ont passé de nouvelles commandes via le distributeur. La direction a souligné que LockeT est économique, améliore le flux de travail et soutient une hémostase rapide permettant une sortie le jour même.
Catheter Precision (NYSE:VTAK) meldete eine schnelle kommerzielle Aufnahme seines LockeT-Verschlussgeräts in Südafrika am 20. November 2025. Zusammen mit dem Distributor HLC Medical und Dr. Heather Henry-Lines wurde LockeT in fünf Krankenhäusern innerhalb von zwei Monaten implementiert; drei Krankenhäuser verwenden LockeT täglich und zwei routinemäßig. Zwei weitere Krankenhäuser warten auf interne Genehmigungen. Alle fünf Krankenhäuser haben Nachbestellungen über den Distributor aufgegeben. Das Management hob LockeT als kosteneffizient, arbeitsablaufverbessernd und unterstützend bei der schnellen Hämostase hervor, die eine Entlassung am selben Tag ermöglicht.
Catheter Precision (NYSE:VTAK) أعلنت عن اعتماد تجاري سريع لجهاز الإغلاق LockeT في جنوب إفريقيا في 20 نوفمبر 2025. مع الموزع HLC Medical والدكتورة Heather Henry-Lines، تم تنفيذ LockeT في خمسة مستشفيات خلال شهرين؛ ثلاثة مستشفيات يستخدمون LockeT يوميًا واثنان بشكل روتيني. مستشفيان إضافيان ينتظران الموافقات الداخلية. جميع المستشفيات الخمسة قدمت طلبات إعادة شراء عبر الموزع. أشارت الإدارة إلى أن LockeT فعال من حيث التكلفة، يحسن سير العمل، ويدعم التجلط السريع الذي يمكّن الخروج في نفس اليوم.
- 5 hospitals implemented within two months
- 3 hospitals using LockeT daily
- All 5 hospitals placed reorders via distributor
- Device described as cost effective and workflow improving
- Adoption limited to five hospitals to date
- 2 hospitals still awaiting internal approvals
FORT MILL, S.C., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market, today announces the rapid commercial uptake of its LockeT closure device in South Africa.
With the assistance of local distributor, HLC Medical and Dr. Heather Henry-Lines, LockeT was successfully implemented in five hospitals within two months. Three of these hospitals are using LockeT daily and the other two hospitals are using LockeT routinely. In addition, two additional hospitals are awaiting internal approvals. All five hospitals have placed reorders of LockeT via VTAK’s distributor.
“The rapid uptake of LockeT in such a short time frame underscores the importance of LockeT in emerging markets”, said Fatih Ayoglu, European Sales Manager at Catheter Precision. He continued, “Emerging markets are conscious of cost, but also require that the products improve workflow while improving and expediting patient care. LockeT fits in nicely because it is cost effective, improves workflow and assists in rapid hemostasis enabling same day discharge.”
About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
Investor Relations
973-691-2000
IR@catheterprecision.com
# # #
FAQ
What did Catheter Precision (VTAK) announce on November 20, 2025 about LockeT in South Africa?
How many South African hospitals use LockeT daily as of Nov 20, 2025?
What does the LockeT reorder activity mean for VTAK distribution in South Africa?
Are more South African hospitals expected to adopt LockeT after Nov 20, 2025?
What clinical or operational benefits did Catheter Precision cite for LockeT (VTAK)?
